Equities

Cisen Pharmaceutical Co Ltd

603367:SHH

Cisen Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.83
  • Today's Change-0.23 / -1.91%
  • Shares traded2.14m
  • 1 Year change-11.39%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,7282,7822,417
Total Receivables, Net1,3711,2891,073
Total Inventory708580595
Prepaid expenses1169253
Other current assets, total472.277.11
Total current assets4,9704,7454,145
Property, plant & equipment, net1,4671,4961,611
Goodwill, net------
Intangibles, net212213211
Long term investments607270313
Note receivable - long term------
Other long term assets------
Total assets7,3386,8156,364
LIABILITIES
Accounts payable401415435
Accrued expenses153180155
Notes payable/short-term debt393365369
Current portion long-term debt/capital leases3.340.302.72
Other current liabilities, total420322258
Total current liabilities1,3701,2821,219
Total long term debt13310111
Total debt529466382
Deferred income tax13113.87
Minority interest39240.75
Other liabilities, total566574
Total liabilities1,6101,4831,309
SHAREHOLDERS EQUITY
Common stock453453453
Additional paid-in capital1,9191,9131,863
Retained earnings (accumulated deficit)3,3582,9892,774
Treasury stock - common(0.08)(20)(33)
Unrealized gain (loss)------
Other equity, total(2.69)(2.93)(3.07)
Total equity5,7275,3325,055
Total liabilities & shareholders' equity7,3386,8156,364
Total common shares outstanding453450450
Treasury shares - common primary issue0.012.983.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.